title: Towards a cross-species pharmacology of sensorimotor gating: effects of amantadine, bromocriptine, pergolide and ropinirole on prepulse inhibition of acoustic startle in rats.
abstract: Animal models in behavioral pharmacology can be evaluated based on their face, predictive and construct validity. A further level of validity may be achieved if a model is reproduced precisely across species--from laboratory animal to human--using identical conditions and manipulations to elicit identical behavioral changes. Under circumstances in which a model achieves 'homologous' validity, it should be possible to demonstrate that the same pharmacological agents produce parallel changes in the same behavior (as distinct from the clinical condition that the animal behaviors are hypothesized to model), when studied in laboratory animals and in humans. Studies have demonstrated that the disruption of sensorimotor gating of the startle reflex, measured by prepulse inhibition (PPI), in rats by dopamine agonists exhibits face, predictive and construct validity for the relative loss of PPI in schizophrenia patients. To assess the homologous validity of this model, and to expand its utility in understanding the pathophysiology of sensorimotor gating deficits and in developing novel antipsychotic agents to reverse these deficits, it will be important to study PPI across species, comparing response profiles to identical pharmacological manipulations. In the present studies, we report that PPI in rats is reduced in a dose-dependent manner by four dopamine agonists that can be administered with relative ease to humans. We also report that the PPI-disruptive effects of the clinically useful dopamine agonist pergolide are reversed by both typical and atypical antipsychotics. These studies establish a foundation for pursuing human pharmacological studies of PPI, and for extrapolating the substantial neurochemical and neurophysiological information from animal studies of PPI, towards understanding the neural basis for deficient sensorimotor gating in specific neuropsychiatric disorders.
authors.affiliation: Department of Psychiatry, UCSD School of Medicine, La Jolla 92093-0804, USA. nswerdlow@ucsd.edu
authors.forename: N R
authors.initials: NR
authors.lastname: Swerdlow
authors.forename: N
authors.initials: N
authors.lastname: Taaid
authors.forename: J L
authors.initials: JL
authors.lastname: Oostwegel
authors.forename: E
authors.initials: E
authors.lastname: Randolph
authors.forename: M A
authors.initials: MA
authors.lastname: Geyer
mesh_terms: D000161:Acoustic Stimulation; D000547:Amantadine / Q000494:pharmacology; D000818:Animals; D001971:Bromocriptine / Q000494:pharmacology; D015259:Dopamine Agents / Q000494:pharmacology*; D018491:Dopamine Agonists / Q000494:pharmacology; D004347:Drug Interactions; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D008297:Male; D010479:Pergolide / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013216:Reflex, Startle / Q000187:drug effects*; D013045:Species Specificity
chemical_list: D015259:Dopamine Agents; D018491:Dopamine Agonists; D007211:Indoles; C046649:ropinirole; D010479:Pergolide; D001971:Bromocriptine; D000547:Amantadine